Alexion Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.05.15	Pre-market Movers For May 6 (WEN, CHK, MGI, WU, WD, GEVA, ALXN, BRDR, FATE, ZU) (RTTNews)
06.05.15	Alexion Pharma To Buy Synageva; Transaction Valued At $8.4 Bln Net Of Cash (RTTNews)
23.04.15	Alexion Pharma Q1 Profit Decreases - Quick Facts (RTTNews)
10.04.15	Alexion Receives Approval For Updates To European Label For Soliris (RTTNews)
08.03.15	Alexion Reports Better Muscle Strength In HPP Children On Asfotase Alfa (RTTNews)
02.03.15	FDA Grants Priority Review For Asfotase Alfa As Treatment For Patients With HPP (RTTNews)
29.01.15	Alexion Pharma Turns To Profit In Q4; Names David Hallal CEO - Quick Facts (RTTNews)
30.12.14	Alexion Completes Rolling Submission Of BLA For Asfotase Alfa - Quick Facts (RTTNews)
15.12.14	Alexion Pharma To Repurchase Up To $500 Mln Of Stock - Quick Facts (RTTNews)
27.11.14	Alexion Pharma : NICE Confirms Soliris Very Effective Treatment For AHUS (RTTNews)
25.11.14	Alexion Says Soliris Granted Orphan Drug Status By Japan's MHLW - Quick Facts (RTTNews)
23.10.14	Alexion Pharma Q3 Profit Soars, Results Beat Estimates; Raises Annual Guidance (RTTNews)
15.10.14	Alexion Pharma Files NDA For Asfotase Alfa In Japan - Quick Facts (RTTNews)
09.10.14	Alexion Pharma Appoints Leonard Bell As Chairman (RTTNews)
17.09.14	Alexion Names David Hallal COO - Quick Facts (RTTNews)
15.09.14	Alexion Reports Improved Survival With Asfotase Alfa In HPP Children (RTTNews)
08.09.14	Alexion Pharma: Asfotase Alfa Granted Orphan Drug Designation In Japan (RTTNews)
25.08.14	Alexion Initiates Registration Trial Of Eculizumab To Prevent DGF (RTTNews)
01.08.14	Alexion : EC Grants Orphan Drug Designation To Soliris To Treat Patients With MG (RTTNews)
17.06.14	Alexion's Soliris Gets Orphan Drug Designation For Treating Myasthenia Gravis (RTTNews)
02.06.14	Alexion Initiates Voluntary Recall Of Certain Lots Of Soliris - Quick Facts (RTTNews)
05.05.14	Alexion: FDA Oks Conversion Of Soliris Accelerated Approval To Regular Approval (RTTNews)
24.04.14	Alexion Q1 Profit Up; Lifts Adj. EPS View, Backs Revenue Outlook For FY14 (RTTNews)
23.04.14	Alexion: EC Orphan Drug Status For Soliris In Prevention Of Graft Rejection (RTTNews)
10.03.14	Alexion Pharma Boosts 2014 Targets - Quick Facts (RTTNews)
04.03.14	NICE Seeks Clarification From Alexion On High Cost For Rare Blood Disorder Drug (RTTNews)
04.03.14	Alexion: NICE Confirms Eculizumab Is Very Effective Treatment For AHUS Patients (RTTNews)
24.02.14	Alexion Pharma: EC Grants Orphan Drug Designation To Soliris - Quick Facts (RTTNews)
30.01.14	Alexion Q4 Adj. Profit, Revenue Beat Estimates; Sees 2014 Results Above View (RTTNews)
21.01.14	Alexion Pharma: FDA Grants Orphan Drug Designation To Soliris (RTTNews)
09.12.13	Alexion Pharma Presents Soliris Data At ASH (RTTNews)
10.11.13	Alexion Pharma: Soliris Inhibits TMA, Improves Renal Function In AHUS Patients (RTTNews)
24.10.13	Alexion Pharmaceuticals Q3 Profit Beats Estimates - Quick Facts (RTTNews)
24.10.13	Alexion: FDA Grants Breakthrough Therapy Designation To CPMP Replacement Therapy (RTTNews)
16.10.13	Successful Launches, Upcoming Conference Calls, Signing of Agreements, and Trial Results - Research Report on Vertex, Illumina, Alexion, VIVUS, and Endocyte (PR Newswire)
02.10.13	Critical Alerts For HSBC, Cree, Santarus, MGM Mirage, and Alexion Pharmaceuticals Released By InvestorsObserver (PR Newswire)
24.09.13	Corporate Restructuring, Recognitions, Drug Approvals, Mergers and Stock Price Movements - Research Report on Agilent, UnitedHealth, Onyx, Alexion, and Opko Health (PR Newswire)
22.09.13	Alexion Pharma Reports Data From Phase 2 Study Of Asfotase Alfa - Quick Facts (RTTNews)
13.09.13	Alexion's Soliris Obtains Marketing Approval In Japan For All Patients With AHUS (RTTNews)
12.09.13	NHS England Commissions Soliris® for the Treatment of Atypical Haemolytic Uraemic Syndrome (aHUS) (PR Newswire)
27.08.13	Critical Alerts For BlackBerry Limited, ConAgra Foods, Aetna, Alexion Pharmaceuticals, and BroadSoft Released By InvestorsObserver (PR Newswire)
02.08.13	Investments in R&D Activities and Strong Product Sales Strengthen Companies' Financial Positions - Research Report on Alexion, Amgen, Vertex, Aegerion, and Acadia (PR Newswire)
25.07.13	Alexion Pharma Q2 Profit Up, Raises FY13 Guidance - Quick Facts (RTTNews)
23.07.13	Increased Demand, Fast Track Designations, and Strong Sales Boost Revenue Growth - Research Report on Alexion, Baxter International, Align Technology, Transition, and OPKO (PR Newswire)
16.07.13	Alexion's Soliris Gets COMP Positive Opinion For Orphan Medicinal Product Status (RTTNews)
06.12.09	Soliris® Reduced Hemolysis, Decreased Transfusion Requirements and Improved Fatigue in Patients with PNH and Bone Marrow Insufficiency Disorders (Businesswire)
05.12.09	Long-Term Soliris® Treatment Resulted in Sustained Reduction in Hemolysis and Improved Kidney Function in Japanese Patients with PNH (Businesswire)
06.08.09	European Commission and U.S. FDA Grant Alexion’s Soliris® (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus
22.11.24		Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen
22.11.24		Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone
22.11.24		Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen
22.11.24		SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester

22.11.24

Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen

22.11.24

Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone

22.11.24

Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen